中国药品价格登记系统上线 助力国产创新药“走出去”

Core Points - The China Drug Price Registration System officially launched on the 2nd, with nine pharmaceutical companies participating in the first batch of price registrations [1] - The National Healthcare Security Administration (NHSA) released an announcement detailing the registration scope, platform, process, and query services, aiming to guide companies in building a more comprehensive drug pricing system [1] - The system operates on the principle of local acceptance, national sharing, and global openness, providing online and offline services for drug price registration queries [2] Group 1 - The registration system allows companies to self-declare drug prices based on their development needs, taking responsibility for the authenticity of the information [1] - The system is independent of provincial medical procurement platforms, enhancing the modernization of drug price governance [2] - By 2025, Chinese pharmaceutical companies completed 103 overseas transactions, with a total transaction amount exceeding $92 billion, highlighting the increasing importance of China's market in the global pharmaceutical industry [1] Group 2 - The establishment of the registration system is a new exploration to address the innovative development of the pharmaceutical sector, providing a platform for companies to build a global and diversified drug pricing system [2] - The system aims to facilitate the internationalization of Chinese innovative drugs and attract more high-quality foreign drugs into the Chinese market, benefiting patients in China [2]